1. Academic Validation
  2. Identification and characterization of a cell cycle and apoptosis regulatory protein-1 as a novel mediator of apoptosis signaling by retinoid CD437

Identification and characterization of a cell cycle and apoptosis regulatory protein-1 as a novel mediator of apoptosis signaling by retinoid CD437

  • J Biol Chem. 2003 Aug 29;278(35):33422-35. doi: 10.1074/jbc.M303173200.
Arun K Rishi 1 Liyue Zhang Madanamohan Boyanapalli Anil Wali Ramzi M Mohammad Yingjie Yu Joseph A Fontana James S Hatfield Marcia I Dawson Adhip P N Majumdar Uwe Reichert
Affiliations

Affiliation

  • 1 Veterans Affairs Medical Center, Department of Internal Medicine and Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA. [email protected]
Abstract

CD437, a novel retinoid, causes cell cycle arrest and Apoptosis in a number of Cancer cells including human breast carcinoma (HBC) by utilizing an undefined retinoic acid receptor/retinoid X receptor-independent mechanism. To delineate mediators of CD437 signaling, we utilized a random antisense-dependent functional knockout genetic approach. We identified a cDNA that encodes approximately 130-kDa HBC cell perinuclear protein (termed CARP-1). Treatments with CD437 or chemotherapeutic agent adriamycin, as well as serum deprivation of HBC cells, stimulate CARP-1 expression. Reduced levels of CARP-1 result in inhibition of Apoptosis by CD437 or adriamycin, whereas increased expression of CARP-1 causes elevated levels of cyclin-dependent kinase inhibitor p21WAF1/CIP1 and Apoptosis. CARP-1 interacts with 14-3-3 protein as well as causes reduced expression of cell cycle regulatory genes including c-Myc and cyclin B1. Loss of c-Myc sensitizes cells to Apoptosis by CARP-1, whereas expression of c-Myc or 14-3-3 inhibits CARP-1-dependent Apoptosis. Thus, Apoptosis induction by CARP-1 involves sequestration of 14-3-3 and CARP-1-mediated altered expression of multiple cell cycle regulatory genes. Identification of CARP-1 as a key mediator of signaling by CD437 or adriamycin allows for delineation of pathways that, in turn, may prove beneficial for design and targeting of novel antitumor agents.

Figures